---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000239"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:50:19.448191+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reports ~$99M cash; FDA feedback supports 505(b)(2) pathway for RT-102; Phase 2 in H2 2023

## Summary
- Preliminary cash, cash equivalents, restricted cash equivalents and marketable securities of ~$99M as of Dec 31, 2022, subject to audit.
- FDA pre-IND feedback indicates 505(b)(2) pathway suitable for RT-102 (oral PTH analog for osteoporosis); Phase 2 trial expected H2 2023.
- Positive topline Phase 1 repeat-dose results for RT-102 announced in Dec 2022, meeting all endpoints.
- Plans to initiate three additional Phase 1 studies in 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypoparathyroidism), RT-111 (ustekinumab biosimilar).

## SEC filing metadata
- accession: 0000950170-23-000239
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023000239/0000950170-23-000239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023000239/rani-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000239
- JSON: https://secwatch.observer/filing/0000950170-23-000239.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.